BIT Capital GmbH Lowers Position in BridgeBio Pharma, Inc. $BBIO

BIT Capital GmbH lowered its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 94.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,056 shares of the company’s stock after selling 16,504 shares during the period. BIT Capital GmbH’s holdings in BridgeBio Pharma were worth $55,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in BBIO. Jones Financial Companies Lllp acquired a new position in BridgeBio Pharma in the first quarter valued at $35,000. CWM LLC lifted its position in BridgeBio Pharma by 29.8% during the second quarter. CWM LLC now owns 6,830 shares of the company’s stock valued at $295,000 after buying an additional 1,569 shares in the last quarter. Allianz Asset Management GmbH grew its stake in BridgeBio Pharma by 57.7% during the second quarter. Allianz Asset Management GmbH now owns 12,300 shares of the company’s stock worth $531,000 after buying an additional 4,500 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of BridgeBio Pharma in the second quarter worth $229,000. Finally, Phoenix Financial Ltd. purchased a new position in shares of BridgeBio Pharma in the 2nd quarter valued at $209,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other BridgeBio Pharma news, Director Randal W. Scott sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total value of $754,600.00. Following the sale, the director owned 11,589 shares in the company, valued at approximately $874,505.94. This trade represents a 46.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Trimarchi sold 13,600 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total value of $1,016,192.00. Following the transaction, the chief financial officer owned 336,585 shares of the company’s stock, valued at approximately $25,149,631.20. This represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 176,121 shares of company stock valued at $13,009,631. 18.20% of the stock is owned by corporate insiders.

Trending Headlines about BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Strong Phase 3 PROPEL‑3 achondroplasia results improve the program’s regulatory and commercial outlook — a clear fundamental catalyst supporting upside for BBIO. Read More.
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates and bumped its price target to $100 while keeping a Buy rating — analyst upgrades can lift sentiment and buying interest. Read More.
• Neutral Sentiment: Upcoming Q4/2025 earnings and Feb. 24 conference call create a scheduled event risk: results and program/cash‑burn details could drive short‑term volatility either way. Read More.
• Neutral Sentiment: Company granted inducement RSUs to new hires (76,701 shares) — modest ongoing dilution to monitor but not a large immediate overhang. Read More.
• Neutral Sentiment: Small institutional buying: Oppenheimer reported a new 7,845‑share stake per 13F filing — signals some investor interest but immaterial scale. Read More.
• Negative Sentiment: Clustered insider selling on Feb. 17: Director Randal Scott sold 10,000 shares (~$754k) and the CFO sold 13,600 shares (~$1.02M), alongside other officer sales — concentrated disposals are pressuring near‑term sentiment. Read More.
• Negative Sentiment: Smaller CAO sale (510 shares) and a pattern of executive liquidity events — repeated sales by insiders can keep downward pressure until management rebuilds conviction via buying or other signals. Read More.
• Neutral Sentiment: Reported short‑interest data is inconsistent (entries show zero shares / NaN) and does not currently indicate a material short‑squeeze dynamic — treat the short‑interest note as noise until clearer reporting emerges.

BridgeBio Pharma Trading Down 4.3%

BBIO stock opened at $70.72 on Friday. The stock’s 50 day simple moving average is $75.66 and its 200 day simple moving average is $63.84. BridgeBio Pharma, Inc. has a 12-month low of $28.33 and a 12-month high of $84.94. The firm has a market cap of $13.63 billion, a P/E ratio of -16.92 and a beta of 1.13.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BBIO shares. TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Sanford C. Bernstein assumed coverage on shares of BridgeBio Pharma in a research note on Thursday, December 11th. They set an “outperform” rating and a $94.00 price objective on the stock. HC Wainwright raised their price target on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Leerink Partners boosted their price objective on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Finally, Piper Sandler raised their target price on BridgeBio Pharma from $93.00 to $98.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.05.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.